```html

Xeroderma Pigmentosum – Ocular Form

Overview

Xeroderma pigmentosum (XP) is a rare, autosomal‑recessive genetic disorder that impairs the body’s ability to repair DNA damage caused by ultraviolet (UV) radiation. While the classic form of XP involves severe skin sensitivity, the ocular form predominantly affects the eyes, causing early‑onset photophobia, conjunctival changes, and a markedly increased risk of ocular cancers.

Who it affects

• Both sexes equally; no gender predilection.
• Typically diagnosed in childhood, often before age 5.
• Higher prevalence in populations with a high rate of consanguineous marriage (e.g., parts of the Middle East, North Africa, and Japan).

Prevalence

• Worldwide prevalence of all XP types is estimated at 1 in 1 million people, but ranges from 1:250,000 in the United States to 1:22,000 in some Japanese islands.<sup>[1] NIH</sup>
• Ocular involvement is present in >80 % of XP patients, with the ocular form accounting for the majority of morbidity.<sup>[2] Mayo Clinic</sup>

Symptoms

Symptoms of the ocular form may appear early and progress with cumulative UV exposure. They can be grouped by the anatomic structures they affect.

Anterior Segment

• Photophobia – intense discomfort in bright light; often the first symptom.
• Conjunctival xerosis – dryness, redness, and a sand‑paper texture.
• Pinguecula and pterygium – fleshy, fibrovascular growths on the bulbar conjunctiva, usually on the nasal side.
• Conjunctival melanosis – hyperpigmented spots that may evolve into melanoma.
• Corneal clouding/ulceration – due to UV‑induced DNA damage in epithelial cells.
• Limbal stem‑cell deficiency – leading to vascularization, loss of transparency, and recurrent erosions.

Posterior Segment

• Retinal pigmentary changes – mottled hyper‑ and hypopigmentation visible on fundus exam.
• Macular degeneration – early‑onset, often bilateral.
• Optic nerve atrophy – progressive loss of visual acuity.
• Intraocular tumors – especially malignant melanoma of the uvea.

Systemic/Ocular Overlap

• Dry eye syndrome (Schirmer test < 5 mm/5 min).
• Repeated ocular infections due to compromised surface barrier.
• Reduced visual acuity, ranging from mild blur to legal blindness.

Causes and Risk Factors

XP results from pathogenic variants in any of the genes responsible for the nucleotide excision repair (NER) pathway. The most common genes are XPA, XPB (ERCC3), XPC, XPD (ERCC2), XPE (DDB2), XPF (ERCC4), and XPG (ERCC5). Defective NER incapacitates cells from correcting UV‑induced cyclobutane pyrimidine dimers and 6‑4 photoproducts.

Genetic inheritance

• Autosomal recessive – both parents carry one defective allele.
• Carrier frequency varies; in some isolated communities it can be as high as 1 in 30.

Environmental risk factors

• High cumulative UV‑A and UV‑B exposure (e.g., living near the equator, outdoor occupations).
• Insufficient sun‑protective behavior during childhood.

Who is at higher risk?

• Children of consanguineous unions.
• Individuals with a family history of XP or early‑onset skin/eye cancers.

Diagnosis

Diagnosing the ocular form requires a combination of clinical assessment, specialized testing, and genetic confirmation.

Clinical examination

• Detailed slit‑lamp evaluation of the conjunctiva, cornea, and limbus.
• Fundus photography and optical coherence tomography (OCT) to assess retinal changes.
• Assessment of photophobia severity and dry‑eye testing (Schirmer, tear breakup time).

Laboratory & imaging studies

• Skin or conjunctival biopsy – histopathology can reveal DNA repair deficiency markers.
• UV‑induced DNA repair assay – measures the ability of cultured fibroblasts to excise UV lesions.
• Genetic testing – next‑generation sequencing panels targeting the XP genes; results guide prognosis and family counseling.

Diagnostic criteria (simplified)

1. Clinical signs of ocular photosensitivity and pigmentary changes.
2. Documented reduced NER activity or pathogenic biallelic mutation in an XP gene.
3. Exclusion of other photosensitivity disorders (e.g., chronic actinic dermatitis).

Treatment Options

There is no cure for XP; management focuses on minimizing UV exposure, treating complications, and vigilant surveillance for malignancy.

Medications

• Topical lubricants – preservative‑free artificial tears 4–6×/day.
• Cyclosporine A 0.05 % ophthalmic emulsion – improves tear production in refractory dry eye.
• Topical corticosteroids – short courses for acute inflammatory episodes (e.g., pterygium‑related conjunctivitis).
• Systemic retinoids (e.g., isotretinoin) – sometimes used to reduce keratinization and limit new skin lesions; requires dermatologist supervision.

Procedural interventions

• Limbal stem‑cell transplantation – autologous or allogeneic grafts for severe limbal deficiency.
• Phototherapeutic keratectomy (PTK) – removes superficial corneal opacities.
• Excisional surgery or brachytherapy – for conjunctival or intraocular melanoma.
• Regular cataract extraction – cataracts often develop early; modern phacoemulsification yields good visual outcomes.

Lifestyle & protective measures

1. UV‑blocking eyewear – wrap‑around sunglasses with ≥ 400 nm cutoff, rated 100% UV‑A/B protection.
2. Broad‑spectrum sunscreen – SPF 50+ applied to periocular skin every 2 hours outdoors.
3. Protective clothing – wide‑brim hats, UV‑protective caps, and long‑sleeved shirts.
4. Environmental control – install UV‑filtering film on windows at home and in vehicles.

Living with Xeroderma pigmentosum (ocular form)

Successful long‑term management hinges on a structured routine and a supportive care network.

Daily management tips

• Apply sunscreen to the eyelids and surrounding skin each morning, even on cloudy days.
• Carry a spare bottle of preservative‑free artificial tears; reapply whenever eyes feel gritty.
• Schedule a brief “sun‑check” before leaving home: verify that sunglasses, hat, and sunscreen are in place.
• Limit outdoor activities between 10 a.m. and 4 p.m.; if unavoidable, stay in the shade.
• Use a high‑resolution digital device with a blue‑light filter; reduce screen glare that can exacerbate photophobia.
• Maintain a symptom diary (photophobia level, tear film comfort, any new lesions) to discuss at each ophthalmology visit.

Family and psychosocial considerations

• Genetic counseling for siblings and future family planning.
• Connect with patient advocacy groups such as the XP Foundation for emotional support and updates on research.
• School accommodations: provision of UV‑protected classrooms or indoor learning areas.

Prevention

While the genetic defect cannot be prevented, the overwhelming majority of ocular damage is UV‑mediated, making sun‑avoidance strategies essential.

• Implement UV‑protective measures from infancy—parents should dress infants in UV‑blocking clothing and use shade.
• Educate caregivers and school personnel about the need for constant eye protection.
• Annual ophthalmic examinations starting at diagnosis, with earlier and more frequent visits if lesions are detected.
• Encourage vitamin D monitoring; supplement only under medical supervision to avoid unnecessary sun exposure.

Complications

If not adequately controlled, the ocular form can lead to serious sequelae:

• Corneal scarring – may require penetrating keratoplasty.
• Severe dry eye syndrome – can progress to neurotrophic keratopathy.
• Conjunctival or intraocular melanoma – high‑grade malignancies with a 10‑20 % lifetime risk in XP patients.<sup>[3] WHO</sup>
• Early‑onset cataracts – often bilateral, necessitating surgery before adulthood.
• Vision loss – cumulative effect of corneal opacity, retinal degeneration, and optic atrophy.
• Secondary infections – bacterial or viral keratitis due to compromised ocular surface.

When to Seek Emergency Care

---

References

1. National Institutes of Health (NIH). “Xeroderma Pigmentosum.” Genetics Home Reference, 2023.
2. Mayo Clinic. “Xeroderma pigmentosum (XP): Symptoms & Causes.” Updated 2024.
3. World Health Organization (WHO). “Global Surveillance of Ocular Cancers.” 2022.
4. Cleveland Clinic. “Management of Dry Eye Disease.” 2024.
5. CDC. “Ultraviolet (UV) Radiation.” 2024.

```